Search

Displaying results 1231 - 1240 of 10000 in total
  1. Drug

    4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID

    go.drugbank.com/drugs/DB07925
    Experimental

    Synonyms: 4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID
  2. Drug

    4-(2,2,2-TRIFLUOROETHYL)-L-PHENYLALANINE

    go.drugbank.com/drugs/DB08617
    Experimental

    Synonyms: 4-(2,2,2-TRIFLUOROETHYL)-L-PHENYLALANINE
  3. Drug

    3-(4-nitrophenyl)-1H-pyrazole

    go.drugbank.com/drugs/DB08695
    Experimental

    Synonyms: 3-(4-nitrophenyl)-1H-pyrazole
  4. Drug

    4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline

    go.drugbank.com/drugs/DB02984
    Experimental

    Synonyms: 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  5. Drug

    2-(Thiomethylene)-4-Methylpentanoic Acid

    go.drugbank.com/drugs/DB02996
    Experimental

    Synonyms: 2-(Thiomethylene)-4-Methylpentanoic Acid
  6. Drug

    Selenazole-4-carboxyamide-adenine dinucleotide

    go.drugbank.com/drugs/DB03070
    Experimental

    Synonyms: Selenazole-4-carboxyamide-adenine dinucleotide
  7. Drug

    4-methylthio-2-oxobutanoic acid

    go.drugbank.com/drugs/DB02238
    Experimental

    Synonyms: 2-Keto-4-methylthiobutyric acid, 2-Oxo-4-thiomethylbutyric acid
  8. Drug

    2-Aminoquinazolin-4(3h)-One

    go.drugbank.com/drugs/DB03780
    Experimental

    Synonyms: 2-Aminoquinazolin-4(3h)-One
  9. Drug

    Scarlet red

    go.drugbank.com/drugs/DB19136
    ApprovedWithdrawn

    Scarlet red is under investigation in clinical trial NCT00591916 (New Treatment for Donor Sites).

    Categories: Compounds used in a research, industrial, or household settingSynonyms: 2-naphthol, 1-(4-o-tolylazo-o-tolylazo)-, 1-((2-methyl-4-((2-methylphenyl)azo)phenyl)azo)-2-naphthalenol
  10. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-